Ftse Mib
34.519,03
0,15%
DAX
18.698,12
0,06%
S&P 500
5.309,66
0,79%
NASDAQ
16.920,57
1,10%
Bitcoin
68.266,68
0,50%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Regenerx Biopharmaceuticals (RGN) Regenerx Biopharmaceuticals (RGN) Notizie

RGN

Regenerx Biopharm In (RGN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:RGN
DataOraFonteTitoloSimboloCompagnia
22/12/201015:16Business WireFirst Patient Screened in Phase 2 Trial with RegeneRx’s RGN-259 for Dry Eye SyndromeAMEX:RGNRegenerx Biopharmaceuticals
21/12/201022:31Edgar (US Regulatory)Current report filing (8-K)AMEX:RGNRegenerx Biopharmaceuticals
20/12/201016:00Business WireRegeneRx’s Scientific Advisory Board Member Receives 2011 Camras AwardAMEX:RGNRegenerx Biopharmaceuticals
09/12/201016:51Business WireRegeneRx Receives Mexican Patent for the Use of TB4 for Prevention and Treatment of Cardiac DamageAMEX:RGNRegenerx Biopharmaceuticals
01/12/201016:30Business WireRegeneRx Receives Australian Patent Using TB4 to Protect Against Biological, Chemical and Toxic AgentsAMEX:RGNRegenerx Biopharmaceuticals
30/11/201019:41Business WireResearchers Identify Potential Thymosin Beta 4 ReceptorAMEX:RGNRegenerx Biopharmaceuticals
17/11/201015:35Business WireRegeneRx Receives Australian Patent Using Tβ4 for Treatment Of Gastrointestinal DisordersAMEX:RGNRegenerx Biopharmaceuticals
16/11/201020:30Business WireRegeneRx President and CEO to Present at Maxim Group Growth ConferenceAMEX:RGNRegenerx Biopharmaceuticals
12/11/201012:09Edgar (US Regulatory)Quarterly Report (10-Q)AMEX:RGNRegenerx Biopharmaceuticals
02/11/201012:30Business WireRegeneRx Reports Positive Results of Preclinical Dry Eye StudyAMEX:RGNRegenerx Biopharmaceuticals
01/11/201021:30Business WireRegeneRx Receives Non-compliance Notice from NYSE Amex; Intends to Request HearingAMEX:RGNRegenerx Biopharmaceuticals
01/11/201017:56Business WireRegeneRx Awarded $733,438 from U.S. Government Under the Patient Protection and Affordable Care ActAMEX:RGNRegenerx Biopharmaceuticals
26/10/201017:07Business WireRegeneRx Announces Letter to Stockholders Posted on WebsiteAMEX:RGNRegenerx Biopharmaceuticals
14/09/201015:08Business WireRegeneRx Announces TB4 Stroke Study to be Honored at American Heart Association Scientific SessionsAMEX:RGNRegenerx Biopharmaceuticals
07/09/201016:35Business WireRegeneRx President and CEO to Speak at Rodman & Renshaw Annual Global Investment ConferenceAMEX:RGNRegenerx Biopharmaceuticals
03/09/201023:41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:RGNRegenerx Biopharmaceuticals
03/09/201023:22Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:RGNRegenerx Biopharmaceuticals
02/09/201013:00Business WireRegeneRx Appoints R. Don Elsey to Board of DirectorsAMEX:RGNRegenerx Biopharmaceuticals
20/08/201022:01Edgar (US Regulatory)Prospectus filed pursuant to Rule 424(b)(3) (424B3)AMEX:RGNRegenerx Biopharmaceuticals
02/08/201014:30Business WireBritish Researchers Report that TB4 is Essential to Heart DevelopmentAMEX:RGNRegenerx Biopharmaceuticals
21/07/201022:48Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)AMEX:RGNRegenerx Biopharmaceuticals
19/07/201018:30Business WireResearchers Report in Neuroscience that TB4 Improves Neurological Function after StrokeAMEX:RGNRegenerx Biopharmaceuticals
14/07/201019:12Edgar (US Regulatory)Amended Statement of Beneficial Ownership (SC 13D/A)AMEX:RGNRegenerx Biopharmaceuticals
08/07/201014:30Business WireRegeneRx Awarded Australian Patent for New TB4 ApplicationsAMEX:RGNRegenerx Biopharmaceuticals
03/06/201017:10Business WireHenry Ford Study: Synthetic Peptide May Regenerate Brain Tissue in Stroke VictimsAMEX:RGNRegenerx Biopharmaceuticals
02/06/201022:05Business WireRegeneRx Announces Exercise of Over-Allotment Option for Recent Public OfferingAMEX:RGNRegenerx Biopharmaceuticals
01/06/201012:04Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)AMEX:RGNRegenerx Biopharmaceuticals
01/06/201012:04Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (DEFA14A)AMEX:RGNRegenerx Biopharmaceuticals
25/05/201014:30Business WireAnnals of the New York Academy of Sciences Publishes Thymosin Beta 4 Research PapersAMEX:RGNRegenerx Biopharmaceuticals
24/05/201014:30Business WireResearchers Report Thymosin Beta 4 Significantly Reduces Damage from Traumatic Brain Injury & Improves Brain Function in Expe...AMEX:RGNRegenerx Biopharmaceuticals
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:RGN

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
TITR
Telecom Italia
BIT
BPE
Bper Banca
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network